Research programme: small molecule sphingosine kinase activators - NeoPharmAlternative Names: K 6PC-5; small molecule sphingosine kinase activators research programme - NeoPharm
Latest Information Update: 16 Jul 2016
At a glance
- Originator NeoPharm Co
- Class Small molecules
- Mechanism of Action Sphingosine kinase stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Skin-disorders in South Korea
- 16 Aug 2005 Preclinical trials in Skin disorders in South Korea (unspecified route)